Abbott missed analysts’ profit expectations for Q4 2025, yet the company’s full year financials were buoyed by strong ...

Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott Laboratories' January price pullback is a signal to load up on shares; this Dividend Aristocrat is growing its ...

Abbott Laboratories raised its dividend 7% and targets $5.80 EPS with 19.2x forward P/E and double-digit profit growth. See ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott's Medical Devices segment, especially CGM, continues to deliver robust double-digit growth, offsetting Nutrition ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Texas Gov. Greg Abbott has banned state employees from using Chinese-linked technology—including Shein, Temu, Alibaba, and TP ...

The medical device maker announced it anticipates first quarter adjusted profits per share between $1.12 and $1.18, trailing ...

Abbott Laboratories stock slid Thursday after the medical-products maker reported disappointing results, hit by a slump in the division that makes baby formula and nutrition shakes. Abbott shares ...